Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Merck & Co. signs voluntary licensing agreements with seven generic manufacturers for HIV PrEP pill alimatravir in 129 LMICs
Licensing deal, infectious disease, small molecule, manufacturing - Read more

Meiji Seika Pharma's HBI-8000 plus nivolumab meets Ph3 progression-free survival endpoint in advanced melanoma
Small molecule, cancer, epigenetic immunomodulator, melanoma, combination therapy, PD-1 inhibitor - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

Scribe Therapeutics raises nearly $129M IPO, advancing gene editing and ASCVD therapy development
Gene editing, CRISPR, cell therapy, cardiovascular, rare disease, clinical-stage - Read more

China Pharma Holdings closes $5M registered direct offering for working capital purposes
Specialty pharmaceuticals, small molecule - Read more

Codexis prices $23.1M public offering of common stock for working capital, R&D
Enzymatic solutions, oligonucleotide therapeutics, manufacturing, platform technology - Read more

Fresenius launches €200M ($227.5M) corporate venture capital fund targeting biopharma, MedTech, and digital care innovation
Corporate venture capital, biopharma, medtech, strategic, major transaction - Read more

Scancell acquires Neuphoria Therapeutics via reverse merger, securing Nasdaq listing and $89M financing
DNA vaccine, oncology, major transaction, financial - Read more

OpenAI officially launches ChatGPT Health for US users amid lawsuits over harmful medical advice
Digital health AI, general wellness, competitive, legal liability - Read more

Amgen submits data package to FDA seeking hearing to defend Tavneos' U.S. market status
Small molecule, rare disease, regulatory, competitive - Read more

FDA panel endorses lifting restrictions on four peptides for compounding pharmacies use
Peptide therapy, wound healing, autoimmune, regulatory - Read more

Roche discontinues Carmot obesity asset acmopatide, backs enicepatide showing 22.5% weight loss potential
GLP-1 agonist, obesity, strategic, pipeline - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Sanofi halts Ph3 amlitelimab (OX40 ligand blocker) development for atopic dermatitis citing insufficient efficacy and safety data
Antibody, autoimmune, monoclonal antibody, atopic dermatitis, celiac disease - Read more

Ipsen's Bylvay (odevixibat) fails Ph3 trial primary endpoint in biliary atresia patients post-Kasai surgery
Small molecule, liver disease, IBAT inhibitor, biliary atresia, cholestatic liver disease, pediatric - Read more

Summit Therapeutics faces under one-year cash runway as FDA verdict for ivonescimab approaches November 14
Bispecific antibody, oncology, financial, regulatory - Read more

Novo Nordisk escalates false advertising lawsuit against Eli Lilly, seeking injunction to halt GLP-1 comparative ads
GLP-1 agonist, obesity, competitive, false advertising - Read more

Senate committee delays vote on Trump's CDC nominee Erica Schwartz amid attendance issues
CDC, public health, operational - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here